Georgina V. Long
University of Sydney(AU)The University of Sydney(AU)Mater Health Services(AU)China Pharmaceutical University(CN)Royal North Shore Hospital(AU)Royal North Shore Hospital(AU)Sydney Hospital(AU)ARC Centre of Excellence in Synthetic Biology(AU)Melanoma Institute Australia(AU)Northern Sydney Local Health District(AU)Suzhou Research Institute(CN)Woodlands Health Campus(SG)Westmead Institute for Medical Research(AU)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
- → Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
- → Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
- → Nivolumab in Previously Untreated Melanoma without BRAF Mutation(2014)5,311 cited
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations(2012)2,783 cited
- →